01041nas a2200313   4500000000100000000000100001000000100002008004100003653001100044653007100055653005600126653001900182653004300201653006600244653004100310653005300351653002700404653001700431653002100448653002500469100001500494700001600509700001300525700001500538245013800553250001500691490000700706020001400713       2023                            d10aHumans10a*Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications10a*Dipeptidyl-Peptidase IV Inhibitors/adverse effects10aCohort Studies10aSulfonylurea Compounds/adverse effects10a*Skin Neoplasms/chemically induced/epidemiology/complications10a*Melanoma/epidemiology/complications10aDipeptidyl-Peptidases and Tripeptidyl-Peptidases10aDipeptidyl Peptidase 410aDrug Effects10aMedical Oncology10apharmacoepidemiology1 aR. Pradhan1 aO. H. Y. Yu1 aR. Platt1 aL. Azoulay00aDipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study  a2023/11/110 v11  a2052-4897